Details for New Drug Application (NDA): 062032
✉ Email this page to a colleague
The generic ingredient in ERYPAR is erythromycin stearate. There are one hundred and three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for 062032
Tradename: | ERYPAR |
Applicant: | Parke Davis |
Ingredient: | erythromycin stearate |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 250MG BASE | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 500MG BASE | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No |
Complete Access Available with Subscription